Several days ago, Ocugen (NASDAQ:OCGN) was an early-stage biotech company focusing on gene therapy to cure eye diseases. And then everything changed. All of a sudden, investors began piling into the shares, and the company joined the center stage of the stock market with the likes of Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,